In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Enlivex, with a price target of $7.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors that highlight the promising potential of Enlivex’s Allocetra treatment for knee osteoarthritis. The recent positive top-line data from the Phase 1/2 trial demonstrated significant improvements in both knee pain and function, particularly in patients over 60 years of age. These results are not only clinically meaningful but also statistically significant, showcasing Allocetra’s impact on key endpoints commonly used in Phase 3 trials for knee osteoarthritis.
Moreover, Allocetra has shown a favorable safety profile with no severe adverse events, which further strengthens its potential as a viable treatment option. Enlivex’s ongoing research into other osteoarthritis sub-indications, such as basal thumb OA and TMJ OA, indicates a strategic approach to expanding the applicability of Allocetra. The upcoming data releases from these studies could pave the way for regulatory approval or partnerships, adding further value to the company’s prospects. These factors collectively support the Buy rating with a 12-month price target of $7.